Innovations in oligonucleotide drug delivery

Journal of Pharmaceutical Sciences

Volumn 92, Issue 8, 2003, Pages 1559-1573

  Lysik, Melanie A ^a   Wu Pong, Susanna ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Carrier mediated delivery; Delivery; Liposomes; Novel delivery methods; Oligonucleotide; Uptake

Indexed keywords

CYCLODEXTRIN; DENDRIMER; FOMIVIRSEN; LIPOSOME; NANOPARTICLE; OLIGONUCLEOTIDE; PEPTIDE DERIVATIVE;

ANIMAL CELL; CELL TRANSPORT; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG UPTAKE; ELECTROPORATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; NONHUMAN; SHORT SURVEY; ULTRASOUND;

EID: 0043212038     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10399     Document Type: Short Survey

References (124)

1. Zamecnik PC, Stephenson ML. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280-284.
2. Stephenson ML, Zamecnik PC. 1978. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75:285-288.
3. Crooke ST. 2000. Progress in antisense technology: the end of the beginning. Methods Enzymol 313:3-45.
4. Stull RA, Szoka FC Jr. 1995. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm Res 12:465-483.
5. Helene C, Toulme JJ. 1990. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99-125.
6. Klinman DM, Barnhart KM, Conover J. 1999. CpG motifs as immune adjuvants. Vaccine 17:19-25.
7. Krieg AM. 2000. CpG oligonucleotides as immune adjuvants. Ernst Schering Res Found Workshop 30:105-118.
8. Krieg AM. 2000. Immune effects and mechanisms of action of CpG motifs. Vaccine 19:618-622.
9. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833-10837.
10. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. 1988. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA 85:1028-1032.
11. Marti G, Egan W, Noguchi P, Zon G, Matsukura M, Broder S. 1992. Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. Antisense Res Dev 2:27-39.
12. Peyman A, Uhlmann E. 1996. Minimally modified oligonucleotides-combination of end-capping and pyrimidine-protection. Biol Chem Hoppe Seyler 377:67-70.
13. Uhlmann E, Ryte A, Peyman A. 1997. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev 7:345-350.
14. Gilar M, Belenky A, Budman Y, Smisek DL, Cohen AS. 1998. Impact of 3′-exonuclease stereoselectivity on the kinetics of phosphorothioate oligonucleotide metabolism. Antisense Nucleic Acid Drug Dev 8:35-42.
15. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. 1991. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 19:5543-5550.
16. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV. 1989. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454-6458.
17. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM. 1989. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474-3478.
18. Zamecnik P, Aghajanian J, Zamecnik M, Goodchild J, Witman G. 1994. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc Natl Acad Sci USA 91:3156-3160.
19. Farrell CL, Bready JV, Kaufman SA, Qian YX, Burgess TL. 1995. The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Antisense Res Dev 5:175-183.
20. Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA. 1993. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32:4855-4861.
21. Wu-Pong S, Weiss TL, Hunt CA. 1992. Antisense c-myc oligodeoxyribonucleotide cellular uptake. Pharm Res 9:1010-1017.
22. Wu-Pong S, Weiss TL, Hunt CA. 1994. Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev 4:155-163.
23. Wu-Pong S, Bard J, Huffman J, Jimerson J. 1997. Oligonucleotide biological activity: Relationship to the cell cycle and nuclear transport. Biol Cell 89:257-261.
24. Wu-Pong S. 2000. Alternative interpretations of the oligonucleotide transport literature: Insights from nature. Adv Drug Deliv Rev 44:59-70.
25. Laktionov P, Dazard JE, Piette J, Vives E, Rykova E, Vlassov V, Lebleu B. 1999. Uptake of oligonucleotides by keratinocytes. Nucleosides Nucleotides 18:1697-1699.
26. Noonberg SB, Garovoy MR, Hunt CA. 1993. Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol 101:727-731.
27. Iversen PL, Zhu S, Meyer A, Zon G. 1992. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 2:211-222.
28. Chin DJ, Green GA, Zon G, Szoka FC Jr, Straubinger RM. 1990. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol 2:1091-1100.
29. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B. 1991. Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88:2702-2706.
30. Fimmel S, Saborowski A, Orfanos CE, Zouboulis CC. 2000. Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells. Horm Res 54:306-311.
31. Stuart DD, Allen TM. 2000. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta 1463:219-229.
32. Lappalainen K, Urtti A, Jaaskelainen I, Syrjanen K, Syrjanen S. 1994. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells. Antiviral Res 23:119-130.
33. Lappalainen K, Urtti A, Soderling E, Jaaskelainen I, Syrjanen K, Syrjanen S. 1994. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta 1196:201-208.
34. Zelphati O, Szoka FC Jr. 1996. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 93:11493-11498.
35. Farhood H, Gao X, Son K, Yang YY, Lazo JS, Huang L, Barsoum J, Bottega R, Epand RM. 1994. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci 716:2334; discussion 34-35.
36. Jaaskelainen I, Monkkonen J, Urtti A. 1994. Oligonucleotide-cationic liposome interactions. A physicochemical study. Biochim Biophys Acta 1195:115-123.
37. Thierry AR, Dritschilo A. 1992. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20:5691-5698.
38. Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A. 1993. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 197:818-825.
39. Konopka K, Rossi JJ, Swiderski P, Slepushkin VA, Duzgunes N. 1998. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta 1372:55-68.
40. Shi F, Nomden A, Oberle V, Engberts JB, Hoekstra D. 2001. Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: Down-regulation of the corticotropin-releasing factor receptor. Nucleic Acids Res 29:2079-2087.
41. Legendre JY, Szoka FC Jr. 1992. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes. Pharm Res 9:1235-1242.
42. Ropert C, Lavignon M, Dubernet C, Couvreur P, Malvy C. 1992. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem Biophys Res Commun 183:879-885.
43. Lubrich B, van Calker D, Peschka-Suss R. 2000. Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes. Eur J Biochem 267:2432-2438.
44. Ponnappa BC, Dey I, Tu GC, Zhou F, Aini M, Cao QN, Israel Y. 2001. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-α in rats. J Pharmacol Exp Ther 297:1129-1136.
45. Koltover I, Salditt T, Radler JO, Safinya CR. 1998. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281:78-81.
46. Liu DX, Huang L. 1989. Small, but not large, unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid can be stabilized by human plasma. Biochemistry 28:7700-7707.
47. Waelti ER, Gluck R. 1998. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int J Cancer 77:728-733.
48. Chaudhuri G. 1997. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. Biochem Pharmacol 53:385-391.
49. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. 1995. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA 92:3318-3322.
50. Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen TM, Calabretta B, Ponzoni M. 2000. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: Antitumor effects. J Natl Cancer Inst 92:253-261.
51. Selvam MP, Buck SM, Blay RA, Mayner RE, Mied PA, Epstein JS. 1996. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res 33:11-20.
52. Ma DD, Wei AQ. 1996. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk Res 20:925-930.
53. Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L. 1994. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res 22:4307-4314.
54. Zelphati O, Wagner E, Leserman L. 1994. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. Antiviral Res 25:13-25.
55. Zelphati O, Zon G, Leserman L. 1993. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res Dev 3:323-338.
56. Leonetti JP, Machy P, Degols G, Lebleu B, Leserman L. 1990. Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA 87:2448-2451.
57. Ginobbi P, Geiser TA, Ombres D, Citro G. 1997. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res 17:29-35.
58. Biessen EA, Vietsch H, Rump ET, Fluiter K, Bijsterbosch MK, van Berkel TJ. 2000. Targeted delivery of antisense oligonucleotides to parenchymal liver cells in vivo. Methods Enzymol 314:324-342.
59. Biessen EA, Vietsch H, Rump ET, Fluiter K, Kuiper J, Bijsterbosch MK, van Berkel TJ. 1999. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem J 340:783-792.
60. Michael SI, Huang CH, Romer MU, Wagner E, Hu PC, Curiel DT. 1993. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J Biol Chem 268:6866-6869.
61. Wu GY, Walton CM, Wu CH. 2001. Targeted polynucleotides for inhibition of hepatitis B and C viruses. Croat Med J 42:463-466.
62. Wu GY, Wu CH. 1992. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 267:12436-12439.
63. Chiou HC, Tangco MV, Levine SM, Robertson D, Kormis K, Wu CH, Wu GY. 1994. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. Nucleic Acids Res 22:5439-5446.
64. Liang WW, Shi X, Deshpande D, Malanga CJ, Rojanasakul Y. 1996. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim Biophys Acta 1279:227-234.
65. Fominaya J, Wels W. 1996. Target cell-specific DNA transfer mediated by a chimeric multi-domain protein. Novel non-viral gene delivery system. J Biol Chem 271:10560-10568.
66. Cotten M, Langle-Rouault F, Kirlappos H, Wagner E, Mechtler K, Zenke M, Beug H, Birnstiel ML. 1990. Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci USA 87:4033-4037.
67. Wagner E, Zenke M, Cotten M, Beug H, Birnstiel ML. 1990. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 87:3410-3414.
68. Wu D, Boado RJ, Pardridge WM. 1996. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther 276:206-211.
69. Penichet ML, Kang YS, Pardridge WM, Morrison SL, Shin SU. 1999. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain. J Immunol 163:4421-4426.
70. Stephens AC, Rivers RP. 1997. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. Thromb Res 85:387-398.
71. Deshpande D, Toledo-Velasquez D, Thakkar D, Liang W, Rojanasakul Y. 1996. Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells. Pharm Res 13:57-61.
72. Soukchareun S, Haralambidis J, Tregear G. 1998. Use of Nalpha-Fmoc-cysteine(S-thiobutyl) derivatized oligodeoxynucleotides for the preparation of oligodeoxynucleotide-peptide hybrid molecules. Bioconjug Chem 9:466-475.
73. Soukchareun S, Tregear GW, Haralambidis J. 1995. Preparation and characterization of antisense oligonucleotide-peptide hybrids containing viral fusion peptides. Bioconjug Chem 6:43-53.
74. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. 1997. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25:2730-2736.
75. Bongartz JP, Aubertin AM, Milhaud PG, Lebleu B. 1994. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22:4681-4688.
76. Smith CC, Kulka M, Aurelian L. 2000. Modified adenovirus penton base protein (UTARVE) as a non-replicating vector for delivery of antisense oligonucleotides with antiviral and/or antineoplastic activity. Int J Oncol 17:841-850.
77. Freulon I, Roche AC, Monsigny M, Mayer R. 2001. Delivery of oligonucleotides into mammalian cells by anionic peptides: Comparison between monomeric and dimeric peptides. Biochem J 354:671-679.
78. de La Torre BG, Albericio F, Saison-Behmoaras E, Bachi A, Eritja R. 1999. Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences. Bioconjug Chem 10:1005-1012.
79. Benimetskaya L, Guzzo-Pernell N, Liu ST, Lai JC, Miller P, Stein CA. 2002. Protamine-fragment peptides fused to an sv40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells. Bioconjug Chem 13:177-187.
80. Chaloin L, Vidal P, Lory P, Mery J, Lautredou N, Divita G, Heitz F. 1998. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem Biophys Res Commun 243:601-608.
81. Antopolsky M, Azhayeva E, Tengvall U, Auriola S, Jaaskelainen I, Ronkko S, Honkakoski P, Urtti A, Lonnberg H, Azhayev A. 1999. Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties. Bioconjug Chem 10:598-606.
82. Reed MW, Fraga D, Schwartz DE, Scholler J, Hinrichsen RD. 1995. Synthesis and evaluation of nuclear targeting peptide-antisense oligodeoxynucleotide conjugates. Bioconjug Chem 6:101-108.
83. Dokka S, Rojanasakul Y. 2000. Novel non-endocytic delivery of antisense oligonucleotides. Adv Drug Deliv Rev 44:35-49.
84. Toth G, Schlammadinger J, Szabo G. 1994. DNA uptake stimulating protein from Neurospora crassa enhances DNA and oligonucleotide uptake also in mammalian cells. Biochim Biophys Acta 1219:314-320.
85. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL. 2000. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol 60:83-90.
86. Albers E, Muller BW. 1995. Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst 12:311-337.
87. Brewster ME, Simpkins JW, Hora MS, Stern WC, Bodor N. 1989. The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol 43:231-240.
88. Arima H, Kondo T, Irie T, Uekama K. 1992. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble β-cyclodextrin derivatives and formulation as oleaginous suppository. J Pharm Sci 81:1119-1125.
89. Merkus FW, Verhoef JC, Romeijn SG, Schipper NG. 1991. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588-592.
90. Zhao Q, Temsamani J, Agrawal S. 1995. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Res Dev 5:185-192.
91. Abdou S, Collomb J, Sallas F, Marsura A, Finance C. 1997. β-Cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence. Arch Virol 142: 1585-1602.
92. Epa WR, Greferath U, Shafton A, Rong P, Delbridge LM, Bennie A, Barrett GL. 2000. Downregulation of the p75 neurotrophin receptor in tissue culture and in vivo, using β-cyclodextrinadamantane-oligonucleotide conjugates. Antisense Nucleic Acid Drug Dev 10:469-478.
93. Zhao Q, Temsamani J, Iadarola PL, Agrawal S. 1996. Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem Pharmacol 52:1537-1544.
94. Yoo H, Juliano RL. 2000. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res 28:4225-4231.
95. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, Fujibayashi Y, Konishi J, Brechbiel MW. 2001. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 7:3606-3612.
96. Helin V, Gottikh M, Mishal Z, Subra F, Malvy C, Lavignon M. 1999. Uptake and intracellular distribution of oligonucleotides vectorized by a PAMAM dendrimer. Nucleosides Nucleotides 18:1721-1722.
97. Helin V, Gottikh M, Mishal Z, Subra F, Malvy C, Lavignon M. 1999. Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture. Biochem Pharmacol 58:95-107.
98. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA, Baker JR Jr. 1996. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 24:2176-2182.
99. Couvreur P, Kante B, Roland M, Speiser P. 1979. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci 68:1521-1524.
100. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. 1979. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331-332.
101. Chavany C, Saison-Behmoaras T, Le Doan T, Puisieux F, Couvreur P, Helene C. 1994. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res 11:1370-1378.
102. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Helene C, Saison-Behmoaras T. 1994. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 91:10460-10464.
103. Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C. 1992. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 9:441-449.
104. Zimmer A. 1999. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods 18:286-295, 322.
105. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. 2001. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int J Pharm 214:13-16.
106. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Auclair C, Couvreur P. 2000. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 279:401-406.
107. Nakada Y, Fattal E, Foulquier M, Couvreur P. 1996. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res 13:38-43.
108. De Rosa G, Quaglia F, La Rotonda MI, Appel M, Alphandary H, Fattal E. 2002. Poly(lactide-coglycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. J Pharm Sci 91:790-799.
109. Freytag T, Dashevsky A, Tillman L, Hardee GE, Bodmeier R. 2000. Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J Controlled Release 69:197-207.
110. Lewis KJ, Irwin WJ, Akhtar S. 1998. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotide: Characterization of P(LA-GA) copolymer microspheres in vitro. J Drug Target 5:291-302.
111. Regnier V, De Morre N, Jadoul A, Preat V. 1999. Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int J Pharm 184:147-156.
112. Regnier V, Le Doan T, Preat V. 1998. Parameters controlling topical delivery of oligonucleotides by electroporation. J Drug Target 5:275-289.
113. Regnier V, Preat V. 1998. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm Res 15:1596-1602.
114. Baba M, Iishi H, Tatsuta M. 2000. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Int J Cancer 85:260-266.
115. Zewert TE, Pliquett UF, Langer R, Weaver JC. 1995. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem Biophys Res Commun 212:286-292.
116. Oldenburg KR, Vo KT, Smith GA, Selick HE. 1995. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J Pharm Sci 84:915-921.
117. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L. 1996. Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging. Blood 88:731-741.
118. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, Dzau VJ. 1999. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci USA 96:6411-6416.
119. von der Leyen HE, Braun-Dullaeus R, Mann MJ, Zhang L, Niebauer J, Dzau VJ. 1999. A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. Hum Gene Ther 10:2355-2364.
120. Tschoep K, Hartmann G, Jox R, Thompson S, Eigler A, Krug A, Erhardt S, Adams G, Endres S, Delius M. 2001. Shock waves: A novel method for cytoplasmic delivery of antisense oligonucleotides. J Mol Med 79:306-313.
121. Bao S, Thrall BD, Gies RA, Miller DL. 1998. In vivo transfection of melanoma cells by lithotripter shock waves. Cancer Res 58:219-221.
122. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. 1996. Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther 7:1339-1346.
123. Unger EC, McCreery TP, Sweitzer RH. 1997. Ultrasound enhances gene expression of liposomal transfection. Invest Radiol 32:723-727.
124. Huber PE, Jenne J, Debus J, Wannenmacher MF, Pfisterer P. 1999. A comparison of shock wave and sinusoidal-focused ultrasound-induced localized transfection of HeLa cells. Ultrasound Med Biol 25:1451-1457.